These handouts are designed to complement the expert presentations. We strongly encourage you to view the full sessions before drawing conclusions based solely on the handout content.

This information is current at the time of recording and is subject to change as new information becomes available.

The Future of Sjögren's Treatments: A Patient Seminar on Emerging Therapies in Clinical Trials

November 8, 2025

Janet Church
President and CEO
Sjögren's Foundation®

Thank you to our Seminar Sponsors

GOLD SPONSOR

NOVARTIS

SILVER SPONSORS

AMGEN

argenx

Bristol Myers Squibb™

cullinan THERAPEUTICS

BRONZE SPONSORS

Johnson&Johnson

Otsuka

resolve

Sjögren's FOUNDATION

Overview of Sjögren's Clinical Trials

Janet Church
President and CEO
Sjögren's Foundation®

Fair Balance

The Future of Sjögren's Treatments: *A Patient Seminar on Emerging Therapies in Clinical Trials* will feature an overview of prospective treatments for Sjögren's disease and their respective mechanisms of action. Each presentation will provide an accurate and fair assessment of the risks and benefits of the mechanisms of action for the potential drugs presented, as far as can be known given information that is publicly available at the time of each presentation's recording.

At the time of recording, the presented therapies are in a clinical trial phase. There is no influence on the seminar agenda and content by any agent of the pharmaceutical industry.

Sjögren's Therapies In this Seminar

These companies are Corporate Members of the Sjögren's Foundation with current clinical trials in process.

Sjögren's FOUNDATION

Purpose of Clinical Trials

- Clinical trials are the means by which we evaluate a new drug or device for a particular disease, or medical problem; or an old drug or device for a new application (e.g. methotrexate)
- New treatments are evaluated for safety and efficacy
- Every step of this process is regulated by the FDA (and other countries governing bodies)

Standard Drug Development Process

1. Therapeutic concept and Target Product Profile
2. Asset creation and lab testing
3. Protocol design
4. FDA (USA Federal Drug Administrations) Protocol approval
5. Move to trial
6. Data analysis including risk/benefit analysis
7. Move to FDA for review and approval
8. Prescribing information and patient labeling documents created

From pre-clinical testing to market is an average of 12 years

At any stage, a company can stop or delay the process

Phases of Clinical Trial



- Pre-clinical: in the laboratory with animal subjects
- Phase 1 - healthy volunteers to determine “pharmacology” of a drug
- Phase 2 - to prove an effect, find the right dose and evaluate safety
- Phase 3 - to generate more meaningful data on safety and efficacy
- Phase 4 - primarily performed to evaluate long term safety

Process of Enrollment – Protocol and Eligibility

- Clinical trials are performed according to a plan design called a protocol which is unique to each project
- Protocols define eligibility criteria such as age, gender, duration of illness, prior therapies, other medications you may be taking
- Eligibility criteria fall into 2 categories:
  - inclusion: clinical and laboratory characteristics of your illness
  - exclusion: co-existent illness, prior treatments, history of allergy, etc

Informed Consent

"A process by which a subject *voluntarily* confirms…willingness to participate in a particular trial, after having been *informed* of all aspects of the trial that are relevant to the subject's decision to participate. Informed consent is *documented* by means of a *written, signed and dated* informed consent form."

-International Conference on Harmonization - Good Clinical Practice

Elements of Informed Consent

1. Description of the clinical trial
2. Potential risks and discomforts
3. Potential benefits
4. Alternative treatments available
5. Confidentiality
6. Compensation and medical treatment in event of injury
7. Contact information at the investigative site
8. Voluntary nature of participation and the right to withdraw


Randomised
Double-blind
Controlled

Sjögren's Trials – Protocol and Eligibility

- Must be formally diagnosed with Sjogren's based on the 2016 ACR/EULAR Classification Criteria
- For most trials, must have an ESSDAI Score of 5 or greater, which is moderate to severe activity. One trial offered and arm of under ESSDAI 5 for High Symptom Burden low ESSDAI. (European Sjögren's Syndrome Disease Activity Index)
- Each trial has their own specific inclusion and exclusion criteria on items such as current drugs being taken, other diseases, etc.

2016 ACR/EULAR Classification Criteria

applies to any individual who meets the inclusion criteria,* does not have any of the conditions listed as exclusion criteria,† and has a score of ≥4 when the weights from the five criteria items below are summed

Item	Weight/score
Labial salivary gland with focal lymphocytic sialadenitis and focus score of ≥1 foci/4 mm^2‡	3
Anti-SSA/Ro-positive	3
Ocular Staining Score ≥5 (or van Bijsterveld score ≥4) in at least one eye§¶	1
Schirmer's test ≤5 mm/5 min in at least one eye§	1
Unstimulated whole saliva flow rate ≤0.1 mL/min§**	1

2016 ACR/EULAR criteria. Shiboski 2016

Clinical Trial Endpoints

- Patient Reported Outcomes
  - ESSPRI → What the patient feels (dryness, fatigue, pain)
  - PROMIS
  - Other patient reported findings
  - Wearables
  - Patient Diary
- Disease Activity Index
  - ESSDAI → What the doctor is measuring (disease activity)
  - ClinESSDAI
  - CRESS
  - STAR

ESSDAI Domains

Constitutional: Measures systemic symptoms like fever, fatigue, and weight loss.

Lymphadenopathy: Assesses enlarged lymph nodes and the potential for lymphoma.

Glandular: Involves swelling of the salivary and tear glands but specifically excludes dryness.

Articular: Evaluates joint pain and stiffness, particularly in the hands, ankles, and feet.

Cutaneous: Includes skin lesions such as vasculitis, purpura, and erythema multiforme.

Pulmonary: Covers various lung diseases.

Renal: Measures kidney-related manifestations.

Muscular: Assesses muscular involvement, such as myositis.

Peripheral Nervous System (PNS): Includes neurologic complications outside of the brain and spinal cord.

Central Nervous System (CNS): Focuses on neurologic complications affecting the brain and spinal cord.

Hematological: Looks at blood-related issues like low red blood cells, neutrophils, lymphocytes, or platelets.

Biological: Assesses laboratory findings such as low complement, high or low IgG, or cryoglobulinemia.

ClinESSDAI removes the biological domain

Measuring Sjögren's Outcomes

Patient symptoms – ESSPRI → Subjective →

Average of the three scores is used

Clinically significant if >=5



1) How severe has your **dryness** been during the last 2 weeks?

No dryness	0	1	2	3	4	5	6	7	8	9	10	Maximal imaginable dryness

2) How severe has your **fatigue** been during the last 2 weeks?

No fatigue	0	1	2	3	4	5	6	7	8	9	10	Maximal imaginable fatigue

3) How severe has your **pain** (joint or muscular pains in your arms or legs) been during the last 2 weeks?

No pain	0	1	2	3	4	5	6	7	8	9	10	Maximal imaginable pain

FINAL ESSPRI SCORE ____

Systemic features – ESSDAI → Objective →

Low DA : <5

Moderate DA: 5-13

High DA: >13

Domain	Activity level	Description
Articular *Exclusion of osteoarthritis*	No=0	Absence of currently active articular involvement
	Low=2	Arthralgias in hands, wrists, ankles and feet accompanied by morning stiffness (>30 min)
	Moderate=4	1–5 (of 28 total count) synovitis
	High=6	≥6 (of 28 total count) synovitis

ESSDAI and ESSPRI poorly correlate – Should be measured simultaneously for a "complete picture"

ESSDAI/ClinESSDAI Certification Program

- Training to ensure consistent and accurate disease activity measurement
- All Corporate members have licensed this training from the Foundation
- Over 4,400 investigators worldwide have taken our certification program
- Professional materials accessible: Clinical Practice Guidelines and more

STEP

SJÖGREN'S TRAINING & EDUCATION PLATFORM



Sjögren's FOUNDATION

Sjögren's Trials & Therapies Presented in Seminar November 8, 2025

Company and Trial name	Therapy	Trial Phase	Enrolling
Novartis NEPTUNUS	ianalumab	Phase 3 Data Announced	Extended Active/ Not Recruiting
BMS POETYK	deucravacitinib	Phase 3	Active/Not Recruiting
Amgen (Horizon) Oasiz	dazodalibep	Phase 3	301 – Active/ Not Recruiting 303 – Active/Recruiting
argenx Unity	efgartigimod	Phase 3	Active/ Recruiting
Johnson & Johnson DAFFODIL	nipocalimab	Phase 3	Active/ Recruiting
Amgen AMG-329 (previously HZN-1116)	HZN-1116	Phase 2	Active/ Not Recruiting
Otsuka	sibeprenlimab	Phase 2	Active/ Recruiting
Resolve Therapeutics	RSLV-132	Phase 2	Active/ Recruiting (female only)
Cullinan Therapeutics	T-Cell Engager	Phase 1	Active/ Recruiting

www.sjogrens.org
clinicaltrials.gov

Thank You!